RT Journal Article
SR Electronic
T1 Microbial signatures in the lower airways of mechanically ventilated COVID19 patients associated with poor clinical outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.23.21252221
DO 10.1101/2021.02.23.21252221
A1 Sulaiman, Imran
A1 Chung, Matthew
A1 Angel, Luis
A1 Tsay, Jun-Chieh J.
A1 Wu, Benjamin G.
A1 Yeung, Stephen T.
A1 Krolikowski, Kelsey
A1 Li, Yonghua
A1 Duerr, Ralf
A1 Schluger, Rosemary
A1 Thannickal, Sara A.
A1 Koide, Akiko
A1 Rafeq, Samaan
A1 Barnett, Clea
A1 Postelnicu, Radu
A1 Wang, Chang
A1 Banakis, Stephanie
A1 Perez-Perez, Lizzette
A1 Jour, George
A1 Shen, Guomiao
A1 Meyn, Peter
A1 Carpenito, Joseph
A1 Liu, Xiuxiu
A1 Ji, Kun
A1 Collazo, Destiny
A1 Labarbiera, Anthony
A1 Amoroso, Nancy
A1 Brosnahan, Shari
A1 Mukherjee, Vikramjit
A1 Kaufman, David
A1 Bakker, Jan
A1 Lubinsky, Anthony
A1 Pradhan, Deepak
A1 Sterman, Daniel H.
A1 Weiden, Michael
A1 Hegu, Adriana
A1 Evans, Laura
A1 Uyeki, Timothy M.
A1 Clemente, Jose C.
A1 De wit, Emmie
A1 Schmidt, Ann Marie
A1 Shopsin, Bo
A1 Desvignes, Ludovic
A1 Wang, Chan
A1 Li, Huilin
A1 Zhang, Bin
A1 Forst, Christian V.
A1 Koide, Shohei
A1 Stapleford, Kenneth A.
A1 Khanna, Kamal M.
A1 Ghedin, Elodie
A1 Segal, Leopoldo N.
YR 2021
UL http://medrxiv.org/content/early/2021/02/26/2021.02.23.21252221.abstract
AB Mortality among patients with COVID-19 and respiratory failure is high and there are no known lower airway biomarkers that predict clinical outcome. We investigated whether bacterial respiratory infections and viral load were associated with poor clinical outcome and host immune tone. We obtained bacterial and fungal culture data from 589 critically ill subjects with COVID-19 requiring mechanical ventilation. On a subset of the subjects that underwent bronchoscopy, we also quantified SARS-CoV-2 viral load, analyzed the microbiome of the lower airways by metagenome and metatranscriptome analyses and profiled the host immune response. We found that isolation of a hospital-acquired respiratory pathogen was not associated with fatal outcome. However, poor clinical outcome was associated with enrichment of the lower airway microbiota with an oral commensal (Mycoplasma salivarium), while high SARS-CoV-2 viral burden, poor anti-SARS-CoV-2 antibody response, together with a unique host transcriptome profile of the lower airways were most predictive of mortality. Collectively, these data support the hypothesis that 1) the extent of viral infectivity drives mortality in severe COVID-19, and therefore 2) clinical management strategies targeting viral replication and host responses to SARS-CoV-2 should be prioritized.Competing Interest StatementThe authors have declared no competing interest.Funding StatementR37 CA244775 (LNS, NCI/NIH); R01 HL125816 (LNS, SBK, NHLBI/NIH); Colton Pilot Project Grant (LNS, LA, SBL, KK); UWSC12030 (LNS, RP, LE, CDC Foundation); PACT grant (LNS, FNIH); R21 AI158997 (SK); R01 AI143861 (KMK, NIAID/NIH); R01 AI143861-02S1 (KMK, NIAID/NIH); R01 DK110014 (HL and CW, NIDDK/NIH); P20 CA252728 (CW and HL, NCI/NIH) American Association for Cancer Research Grant (HP/LNS); The Genome Technology Center is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center (AH, AT); FAMRI Young Clinical Scientist Award (BGW), Stony Wold-Herbert Fund Grant-in-Aid/Fellowship (IS, CB). This work was supported in part by the Division of Intramural Research (DIR) of the NIAID/NIH (EG, EDW). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board of New York UniversityAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data are available in NCBI's Sequence Read Archive at the links provided bellow. https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA688510 https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA687506